{"filing":{"accession_number":"0001213900-26-077591","cik":"0001894525","ticker":"APUS","company_name":"Apimeds Pharmaceuticals US, Inc.","form":"8-K","filing_date":"2026-07-13","report_date":null,"primary_document":"ea0297843-8k_apimeds.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1894525/000121390026077591/ea0297843-8k_apimeds.htm"},"events":[{"id":17626,"run_id":15794,"accession_number":"0001213900-26-077591","anchor_item_number":"8.01","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"This disclosure announces the implementation of a 1-for-10 reverse stock split approved by stockholders via written consent on December 1, 2025, with an effective date of July 24, 2026. While a reverse stock split is a capital structure event with operational consequences (trading symbol, CUSIP change, share consolidation), it is fundamentally a governance matter involving stockholder approval and charter amendment. The event is material to investors as it affects share count, trading mechanics, and potential delisting-risk implications, but does not fit the specific categories of exec_appointment, exec_departure, exec_compensation, shareholder_vote_results (which typically refers to voting outcomes on substantive matters), or delisting_risk (which would require an actual delisting notice). Governance_other is the most appropriate classification.","company_name":"Apimeds Pharmaceuticals US, Inc.","ticker":"APUS","filing_date":"2026-07-13","form":"8-K","submitted_at":null,"items":[{"id":16175,"accession_number":"0001213900-26-077591","item_number":"8.01","item_title":"Other Events.","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"This disclosure announces the implementation of a 1-for-10 reverse stock split approved by stockholders via written consent on December 1, 2025, with an effective date of July 24, 2026. While a reverse stock split is a capital structure event with operational consequences (trading symbol, CUSIP change, share consolidation), it is fundamentally a governance matter involving stockholder approval and charter amendment. The event is material to investors as it affects share count, trading mechanics, and potential delisting-risk implications, but does not fit the specific categories of exec_appointment, exec_departure, exec_compensation, shareholder_vote_results (which typically refers to voting outcomes on substantive matters), or delisting_risk (which would require an actual delisting notice). Governance_other is the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-13T20:32:09.076116+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":16175,"accession_number":"0001213900-26-077591","item_number":"8.01","item_title":"Other Events.","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"This disclosure announces the implementation of a 1-for-10 reverse stock split approved by stockholders via written consent on December 1, 2025, with an effective date of July 24, 2026. While a reverse stock split is a capital structure event with operational consequences (trading symbol, CUSIP change, share consolidation), it is fundamentally a governance matter involving stockholder approval and charter amendment. The event is material to investors as it affects share count, trading mechanics, and potential delisting-risk implications, but does not fit the specific categories of exec_appointment, exec_departure, exec_compensation, shareholder_vote_results (which typically refers to voting outcomes on substantive matters), or delisting_risk (which would require an actual delisting notice). Governance_other is the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-13T20:32:09.076116+00:00","company_name":"Apimeds Pharmaceuticals US, Inc.","ticker":"APUS","filing_date":"2026-07-13"}]}